Abstract
Objectives
To examine the association between use of anti-hypertensive drugs and prostate cancer incidence among 48,389 men in the Cancer Prevention Study II Nutrition Cohort.
Methods
Proportional hazards models were used to calculate rate ratios (RR) for use of Beta-Blockers (BBs), Calcium Channel Blockers (CCBs), and ACE Inhibitors (ACE) and incident prostate cancer in time-dependent analyses.
Results
During follow-up from 1997 to 2005, we identified 3,031 cases of incident prostate cancer. Anti-hypertensive use was associated with slightly decreased risk of all (RR = 0.90, 95% CI 0.83–0.98) and organ-confined low-grade prostate cancer (RR = 0.89, 95% CI 0.81–0.99), but was not statistically significantly associated with aggressive-fatal prostate cancer (RR = 0.93, 95% CI 0.79–1.10). BB and ACE inhibitor treatment was associated with an approximately 10% lower risk for all prostate cancer in models adjusted for age and race. These associations were attenuated and lost statistical significance when adjusted for history of heart disease. No trend with duration of use was detected.
Conclusions
These results do not support the hypothesis that anti-hypertensive medication is strongly associated with risk of prostate cancer. Confounding by concurrent illness may explain inverse associations seen in other studies.
Similar content being viewed by others
References
Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ (2008) Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 52(5):818–827. doi:10.1161/HYPERTENSIONAHA.108.113357
Moser M, Franklin SS (2007) Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich) 9(5):316–323. doi:10.1111/j.1524-6175.2007.07152.x
Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G et al (2004) Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 58(1):50–56. doi:10.1002/pros.10294
Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ et al (2004) Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 13(2):255–259. doi:10.1158/1055-9965.EPI-03-0093
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11(8):534–542. doi:10.1016/S1047-2797(01)00246-0
Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92(9):2462–2470. doi:10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L
Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR et al (1993) Incidence of and mortality from cancer in hypertensive patients. BMJ 306(6878):609–611
Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium-channel blockers and risk of cancer. Lancet 349(9051):525–528. doi:10.1016/S0140-6736(97)80084-0
Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B et al (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358(9281):539–544. doi:10.1016/S0140-6736(01)05704-X
Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK et al (2000) Cancer risk and mortality in users of calcium channel blockers: a cohort study. Cancer 89(1):165–170. doi:10.1002/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G
Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR et al (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493–497. doi:10.1016/S0140-6736(96)04277-8
Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541. doi:10.1023/B:CACO.0000036152.58271.5e
Vezina RM, Lesko SM, Rosenberg L, Shapiro S (1998) Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 11(12):1420–1425. doi:10.1016/S0895-7061(98)00176-9
Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG et al (1998) Calcium channel blockers and the risk of cancer. Jama 279(13):1000–1004. doi:10.1001/jama.279.13.1000
Ahr HJ, Bomhard E, Enzmann H, Karbe E, Mager H, Sander E et al (1998) Calcium channel blockers and the risk of cancer: a preclinical assessment. Cardiovasc Drugs Ther 12(2):157–169. doi:10.1023/A:1007727010076
Sugimoto K, Simard J, Haagensen DE, Labrie F (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J Steroid Biochem Mol Biol 51(3–4):167–174. doi:10.1016/0960-0760(94)90090-6
Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98(3):671–679. doi:10.1172/JCI118838
Palm D, Lang K, Niggemann B, TLt Drell, Masur K, Zaenker KS et al (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118(11):2744–2749. doi:10.1002/ijc.21723
Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort—rationale, study design and baseline characteristics. Cancer 94:2490–2501. doi:10.1002/cncr.101970
Garfinkel L (1985) Selection, follow-up, and analysis in the American Cancer Society prospective studies. Natl Cancer Inst Monogr 67:49–52
Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill JL, Thun MJ, Heath CW (1998) Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 147:556–562
Calle EE, Terrell DD (1993) Utility of the national death index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 137:235–241
Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352(9123):179–184. doi:10.1016/S0140-6736(98)03228-0
Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A (1999) Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 21(5):217–220. doi:10.1023/A:1008741321384
Kehoe R, Wu SY, Leske MC, Chylack LT Jr (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139(8):813–818
Acknowledgement
The authors thank Ms. Christina Newton for her assistance in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodriguez, C., Jacobs, E.J., Deka, A. et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 20, 671–679 (2009). https://doi.org/10.1007/s10552-008-9280-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-008-9280-0